Subscribe
Share
Share
Embed
Opella ditches pharma comms for FMCG brand-building, BelliWelli launches at Walmart with celebs, and new sugar-antibiotic research hands gut health brands a science hook.
Opella is rewriting how consumer healthcare brands market themselves — and BelliWelli's Walmart debut proves culture beats clinical claims at mass retail. Here's what both moves mean for your strategy.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four strong stories lined up for you today.
Klara: We're kicking off with how consumer healthcare brands are raiding the FMCG media playbook — and why that creates a real credibility problem.
Marco: Then kratom's dubious anti-ageing claims are catching regulatory heat across Europe.
Klara: New research on sugar and antibiotics hands gut health brands a proper science hook.
Marco: And BelliWelli's Walmart strategy is worth every marketer's attention. Let's get into it.
Marco: Consumer healthcare brands are ditching the pharma playbook and borrowing from mass consumer goods marketing instead.
Marco: For decades, OTC brands — that's over-the-counter products like cold remedies or vitamins — communicated mostly through clinical language, pharmacy staff recommendations, and cautious advertising. That world is changing fast. Consumers now browse healthcare products the same way they browse shampoo or snacks — on TikTok, on Amazon, comparing reviews and aesthetics as much as efficacy.
Marco: The clearest example right now is Opella, the consumer healthcare spin-off behind brands like Allegra and Dulcolax. They're explicitly shifting their media strategy toward FMCG-style brand-building — meaning high-reach campaigns, entertainment-led content, and emotional storytelling rather than clinical messaging. This mirrors what mass consumer goods giants have done for years in categories like food and personal care.
Marco: From a commercial angle, this makes complete sense. Shelf space in Boots or dm-drogerie markt increasingly goes to brands with strong consumer pull, not just clinical heritage. If your OTC brand doesn't have a social presence, you're invisible to a significant chunk of the buying audience.
Klara: I take that point, but the regulatory risk here is real. In Europe, health claims on OTC and food supplement products are tightly controlled under regulations like EC 1924/2006 — that's the EU law governing what you can actually say a product does. When you go broad and entertainment-led, it becomes very easy to imply benefits you're not legally permitted to state. Regulators notice.
Marco: Which is exactly the tightrope. The brands that master both registers — credible science communication and consumer brand warmth — will dominate. The ones that get lazy and let marketing override compliance will face problems.
Klara: And that's where the real competitive advantage is being built right now.
Marco: Next up, we're moving to our second story.
Klara: Kratom is a psychoactive plant being sold across European wellness and supplement channels on anti-ageing and energy claims that have no credible scientific support whatsoever.
Klara: The longevity and anti-ageing category is booming right now. That boom creates an open door for borderline ingredients to slip in wearing wellness clothing. Kratom is doing exactly that.
Klara: Italian food safety outlet Il Fatto Alimentare has flagged this directly. Their reporting highlights that kratom is circulating with anti-ageing and vitality messaging — while the actual documented risks include dependency and toxicity. Those are serious clinical concerns, not minor footnotes. And under EU novel food regulation, ingredients without an established history of safe consumption in Europe require authorisation before they can be sold. Kratom does not have that authorisation. It also has zero EFSA-approved health claims. None. So every wellness benefit being advertised is legally unsupported.
Marco: From a commercial perspective, this is a cautionary tale for the whole anti-ageing supplement category. Consumers are hungry for longevity solutions right now — that demand is real. But when a high-profile safety story breaks, it doesn't just damage the offending brand. It creates scepticism across the entire category. Legitimate brands with solid formulations get caught in the fallout.
Klara: That's where I'd push back slightly on how the industry frames this. It's not just a reputation risk — it's a patient safety issue. Dependency and toxicity aren't marketing problems. They're harm.
Marco: Agreed. And the brands that will win long-term in anti-ageing are the ones treating ingredient transparency as a genuine differentiator — clearly evidenced actives, clean regulatory status, honest claims. Kratom is a reminder of what the opposite looks like.
Klara: Now let's move to our third story.
Marco: New research suggests that eating a lot of sugar while taking antibiotics makes the damage to your gut bacteria significantly worse.
Marco: Antibiotics save lives, but they're not selective. They wipe out harmful bacteria and beneficial ones alike. That disruption to the gut microbiome — the community of bacteria living in your digestive system — is one of the most documented side effects of antibiotic treatment. What this new study adds is a dietary dimension that the gut health industry has been waiting for.
Marco: Researchers found that higher sugar intake during an antibiotic course was associated with greater microbiome disruption than lower sugar intake. On top of that, the high-sugar group also showed increased growth of potentially harmful bacteria — so you're getting a compounding effect. Antibiotics destabilise the microbiome, and sugar appears to amplify that destabilisation.
Klara: The science here is plausible and the direction of effect makes biological sense. But I want to be careful about how brands run with this. One study is not a settled body of evidence. Before probiotic brands start printing "clinically proven microbiome recovery" on packaging, they need to remember that EFSA's authorised health claims for probiotics remain very limited. The science is promising. The legal claim space is still narrow.
Marco: That's a fair distinction. But the marketing opportunity doesn't require overstating the science. This research opens a very credible conversation. Gut health brands can position probiotics and low-sugar functional foods as active recovery tools during antibiotic treatment — doctor-adjacent messaging that moves these products from optional to genuinely relevant. That's a campaign brief most brands would spend months trying to construct.
Klara: Provided the claims stay within what's actually permitted. The brands that get this right will earn real trust.
Marco: And that trust is worth far more than one opportunistic headline. Let's move to our final story.
Klara: A gut health snack brand just walked into Walmart — and left the science at the door.
Klara: BelliWelli sells fibre-based snacks aimed at people with sensitive digestive systems. Fibre is one of the few areas where EFSA has actually authorised health claims — so there's real science available. But BelliWelli's Walmart launch strategy deliberately parks that science and leads with culture instead.
Klara: The activation combines celebrity cameos, fashion brand collaborations, and consumer giveaways. CEO and co-founder Katie Wilson has been explicit about it — this is a culture-first playbook. The brand is treating fibre the way a streetwear label treats a new drop, not the way a supplement brand treats a clinical dossier.
Marco: And from a commercial standpoint, that's a sharp read of the room. Walmart is not a pharmacy. The shopper browsing the snack aisle is not looking for a gut health lecture. Celebrity association and fashion crossovers lower the barrier to trial dramatically. You're not asking someone to understand the microbiome — you're asking them to pick up something that looks appealing and feels culturally relevant. That's how you move volume in mass retail.
Klara: I understand the logic, and I'm not saying it's wrong. But here's what concerns me. When a brand builds its entire consumer relationship on vibes and celebrity, and the health education comes second — or never — consumers can't make genuinely informed choices. Fibre does have solid authorised claims behind it. There's no reason to hide that. You can be culturally exciting and scientifically honest at the same time.
Marco: That's the smarter long game, actually. The fashion partnerships get people in the door. But the brands that retain those customers are the ones that eventually give them a reason to believe beyond the aesthetic.
Klara: Culture earns the first purchase. Science earns the next ten.
Marco: Today's through-line is clear — gut health is the category where credible science and bold consumer marketing are colliding hardest, and the brands that figure out how to hold both will own the shelf.
Klara: Just make sure the science you lean on is real — because regulators are watching, and so are your consumers.